Many states have taken the slow and steady approach to the legalization of medical and recreation marijuana, but Illinois is doing it homework by sharing the results of a new study detailing the Illinois market demand so if there isn’t over demand or under demand. Steve Grzanich checked in with Pamela Althoff (Executive Director of Medical Cannabis Alliance of Illinois) to sort through what it would mean if legalization happened right now, and what we can continue to do to better ourselves before legalization.
By Azi Paybarah
This week the New Jersey Legislature could pass the most progressive recreational marijuana bill in the country.
New York may not legalize marijuana anytime soon.
My colleagues Nick Corasaniti, who covers New Jersey, and Vivian Wang, who covers the New York Legislature, explained.
What makes New Jersey’s marijuana bill so progressive?
Mr. Corasaniti: Mainly, two things: criminal records and access to the market.
• First, the bill would make it possible to expunge nonviolent criminal records for marijuana-related offenses (up to five pounds, one of the highest thresholds in the country).
People with past convictions, or who are incarcerated or on parole, would be eligible for a clean slate, and they could request expungement online.
• Second, the state would require that at least 10 percent of licenses for marijuana businesses go to small companies. Those licenses would be geared toward low-income or high-crime cities, or ones that have had a lot of marijuana arrests.
Basically, places that have been hit hard by marijuana criminalization would reap some benefits of cannabis legalization.
New Jersey would be the 11th state to legalize marijuana, along with Washington, D.C. Wealthy, white investors have traditionally reaped the profits of the emerging industry.
Where would people be free to consume marijuana?
New Jersey’s bill would allow for “public consumption areas.”
People wouldn’t be able to consume marijuana outdoors in public spaces. There would be designated areas for use, mainly at marijuana dispensaries: buy the drug in one room, and use it in another.
The bill would also allow casinos and hotels to have consumption areas.
Also, the bill would allow marijuana delivery.
Where does New York stand on all this?
Ms. Wang: Legalization felt like an inevitability when Governor Cuomo announced his support for it in December. But that was just three months ago; that’s not a lot of time to figure all this out.
Marijuana for medical purposes can be used in the form of buds, oils, and tinctures. Of these, the market for oil-based marijuana is expected to witness the fastest growth, globally, during the forecast period. Adequate dosage and proper route of administration of cannabinoids are the major areas of concern for healthcare providers. The health benefits of using cannabis oil or hemp oil over smoking marijuana have led to the increased demand for oil-based marijuana for medical applications, thereby contributing to its market growth.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/medical-marijuana-market/report-sample
Globally, North America was the largest revenue generator in the medical marijuana market in 2017, because of high investments in research and development activities to investigate the potential medical applications of cannabinoids. Moreover, Canada and some states of the U.S. are planning to legalize the usage of marijuana for medical as well as recreational purposes. For instance, by October 2018, Canada plans to legalize the drug use by adults. As per the current medical regime associated with cannabis, patients are allowed to access cannabis under the authorization of their healthcare providers. Thus, government initiatives to spread awareness about the medical application of marijuana and legalize its usage are expected to contribute to the market growth in the near future.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=medical-marijuana-market
Several research projects have been funded by the National Institute of Health (NIH) and the National Institute on Drug Abuse (NIDA) to explore the possible benefits of marijuana in different medical conditions. Furthermore, increasing consumption of cannabinoid-based drugs approved for certain disorders is promoting the market growth. For instance, nabiximols (Sativex), a mouth spray containing two cannabinoids of marijuana, that is, tetrahydrocannabinol (THC) and cannabidiol (CBD), is used for treating muscle control problems caused by multiple sclerosis. Nabiximols is approved in the U.K., Canada, and several European countries, and studies are being conducted for the drug approval in the U.S. as well.
By Liz Young Reporter, Albany Business Review
If a GE Power employee tests positive for marijuana use after a manufacturing accident, company managers don’t have a way to figure out when the worker used the drug and whether they were impaired during the accident.
That could be a problem for the employer as lawmakers consider legalizing recreational marijuana in New York, a GE Power executive said.
There isn’t a test for marijuana like there’s a breathalyzer for alcohol that will tell you whether someone is impaired. Weekend users could, in theory, test the same as someone using on the job.
“If we’re legalizing it, we’re going to have lots of positives there,” said Maureen Young, GE Power’s executive counsel on labor and employment. “It’s going to lead to probably some inaccurate disciplinary actions because we can’t test for impairment.”
GE Power is one of many employers in the Albany region facing new challenges and figuring out potential regulations if marijuana becomes legal for recreational use.
Gov. Andrew Cuomo is pushing this year to make New York the 11th state to legalize recreational marijuana. The governor said this week he is dropping his plan to legalize the drug as part of the state’s budget process, but he’s hopeful lawmakers will pass a bill in the weeks that follow.
Bills in the Assembly (A1617) and the state Senate (S1527) would require employers to establish impairment before taking disciplinary action against an employee, and would prevent employers from deciding not to hire people because they test positive for cannabis use.
Young believes figuring out how to test for impairment is critical before marijuana is legalized.
By Eric Sandy
The cannabis market is awash in plant nutrition options. Growers of all experience levels may easily feel daunted by the sheer scope of nutrient program offerings. The range of data points needed to be adequately informed on plant nutrition is also deep; cannabis growers can’t go into this process without knowing precisely what they’re looking to get out of their crops.
With decades experience behind Harrell’s entrance into the cannabis space, the company’s MAX Rx program is set up in a way to fit any grower’s needs. Customization and compatibility are key—not only to what Harrell’s is offering the cannabis industry, but to all growers’ approaches to providing high-quality nutrients to their plants.
It’s vital to understand your own business and the background of any prospective plant nutrition partners, according to Harrell’s Director of Agronomy Jeff Atkinson.
The company was founded in 1941 in Lakeland, Fla. The goal has always been to deliver customized agronomic solutions for a spectrum of plant needs. As cannabis becomes the increasingly competitive marketplace we see today in the U.S., that custom-built product line-up is the sort of thing that will complete cannabis cultivation facilities of all sizes.
Here, Atkins lays out three fundamentals to working through that process and selecting a trustworthy partner. “For us, reputation is everything,” he says.
Cost and Value
“There are a lot of different sources for nutrients out there,” Atkinson says. “We’re able to provide a concentrated, quality product at a cost they likely won’t find.”
Of course, when selecting any vendor for your business, cost is king. Plant nutrition programs should be built into your business to increase yield and profits; if the cost is cutting into your bottom line, then you’re off to a bad start.
“The business is just going to get more competitive,” he says. “There are going to be more constraints on cost and overhead that go into producing these crops. Growers need to understand how much they are really spending on any number of things—lighting, facilities, fertility, … pest control. Once they have that information, they can take a look and say, ‘What are my fertility options? Where can I control my costs and where can I get a consistent product?’”
Before getting into the work of selecting a plant nutrition partner, growers should take a close look at precisely where their own business strengths and weaknesses lie—where to fit a solid program into the balance sheets.
“We look at it as an investment,” Atkinson says. “You get what you pay for.”
This is one of the tentpole mandates that drove Harrell’s to develop the MAX Rx line. Cannabis growers may be coming to the company from all sort of avenues in the industry; Harrell’s, in turn, insists that a plant nutrition partner must provide solutions that are compatible across all types of cultivation. Atkinson says that the company set out to create a line of products for cannabis growers, and that each must be clean, clear and compatible.
Look for the track record of a business.
“By using high-quality ingredients, you know that you’re going to have compatibility between products,” Atkinson says. “You know that they’re going to provide a plant response that you’re looking for—and you know that you’re going to get a good value for the money that you’re investing.”
“All of that [is] so that we have confidence as a company in our products—but, as an extension of that, our customers have confidence in our products, that they’ll do what they say they’ll do, that the customer is getting what we’re telling them they’re buying,” Atkinson says.
Long gone are the days when people were scared of the consequences of cannabis. With the overwhelming growth of the popularity of these green leaves, it is not surprising that more and more researchers are working to establish the efficacy of the CBD products on our health.
While the pros do seem to outweigh the cons as of now, it is also very important to ensure that you don’t necessarily end up consuming it in a dosage that would end up doing you bad than good.
In here, we are going to be discussing the rising popularity of these cannabis rich products and why they are beneficial altogether.
The very first fact about the CBD infused products is the fact that it has amazing benefits in relieving the condition of pain altogether. Several studies have shown that the CBD (cannabidiol) does have the potency to impart beneficial analgesic properties on the body by impacting the endocannabinoid system in the body. The process involved in this is still in the pre-clinical stage of researchers which is why it is beneficial to be cautious of what you are opting for and how much to relieve the signs and symptoms associated with pain.
Amazing for anxiety and depression
Mental health issues are on the constant rise around the globe. With the lack of awareness surrounding it, it is not surprising that the numbers are multiplying with each passing year. CBD has been found to have beneficial impacts in handling the conditions associated with anxiety and depression. CBD oil is believed to be the best potent remedy for handling these conditions. While there are still a number of ongoing researches concerning the same, it is believed that it does help in calming down the overexcited nervous system, thus handling the symptoms effectively.
Prevent cancer risks
Yet another one of the amazing impacts and benefits of CBD is the fact that it helps in keeping the risks of cancer at bay. Studies have found that the administration of this has been quite helpful in handling the symptoms related to cancer and even the side effects that do come along with this treatment process for those who are already suffering. Although the current researches do suggest a positive outlook, more research needs to be done to establish a concrete answer to this.
By Chloe Aiello
As more companies test the waters of the legal hemp and cannabis industries, “it is only inevitable” behemoths in alcohol, tobacco, and consumer goods will start to dominate market share, said Ricardo Baca, cannabis thought leader and founder of public relations firm Grasslands.
“In the same way that we have a strong microbrew market in the beer market, and boutique hotels compared to the big dogs, there will also be the best-of-the-best small cannabis and hemp brands,” said Baca, who also served as editor of The Denver Post’s The Cannabist. “But … these brands that have capital, have reach, they are going to take over market share. We are already seeing it in the U.S. and we are certainly seeing it in Canada.”
His comments came on the heels of news that CVS will start selling CBD products in hundreds of its stores nationwide as part of a deal with Curaleaf Holdings. CVS isn’t the first mainstream brand to embrace the burgeoning hemp and cannabis markets. DSW and Simon Malls now sell CBD products through deals with Green Growth Brands. And Corona-beer maker Constellation Brands ($STZ) and tobacco giant Altria ($MO), which owns Marlboro, have both made significant investments in Canadian cannabis companies.
One by one, varying states are legalizing marijuana to treat a variety of medical conditions, and some states are even legalizing it for recreational use. The cannabis industry is in its very beginnings. Still, there are exciting developments emerging in the field, and despite the marketplace’s freshman status, manufacturing and retail stakeholders are already developing a knack for creating and marketing cannabis products in ways that appeal to mainstream consumers.
The Nuts and Bolts of Cannabis
According to Chad Conner, professor at the Pacific College of Oriental Medicine, one reason that cannabindiol (CBD) products are creating such a stir is that they can affect positive health outcomes among a range of human physiological systems. A recent interview with the professor reveals that CBD is one of more than 100 cannabinoids that work with the human endocannabinoid neurotransmitter system.
For this reason, physicians have been able to successfully treat many conditions. They’ve found success in using CBDs to treat several illnesses, including:
- Neurological problems
- Autoimmune problems
- Immune regulation
- Sleep deprivation
Conner states that the amount of THC in a CBD product is what differentiates various strains of the compound. In other words, the THC content establishes the status of each strain.
Conner reassures that CBD hemp is a safe compound. With the exception of THC, all cannabinoids are non-intoxicating. Even at high doses, CBD is safe, although users may exhibit some minor side effects.
WITH MORE THAN 60% OF AMERICANS BACKING MARIJUANA LEGALIZATION AND SUPPORT GROWING IN D.C., THE CANNABIS INDUSTRY IS POISED TO EXPLODE.
Cannabidiol, commonly referred to as CBD, is a naturally occurring chemical compound called a cannabinoid found in cannabis. Unlike THC, there are no psychoactive effects from ingesting CBD, and the World Health Organization determined it “exhibits no effects indicative of any abuse or dependence potential.” The sector of the burgeoning marijuana industry dedicated to CBD — often sold in the form of hemp extract oil — touts its myriad benefits for multiple maladies. However, the only FDA-approved CBD product is Epidiolex, which is used to treat a rare seizure disorder in children.
“The other CBD products currently being sold are not FDA approved and generally unregulated,” says Dr. Deepak D’Souza, staff psychiatrist at the VA Connecticut Healthcare System and professor of psychiatry at the Yale University School of Medicine. “These products are highly variable in their CBD content and it is therefore difficult to draw conclusions about their purported beneficial effects.”
The WHO’s Expert Committee on Drug Dependence acknowledged “preliminary evidence that CBD may be a useful treatment for a number of other medical conditions” besides seizures. The committee also found “no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD.”